Arterial Cutaneous Femoral Fistulous Tract Closure Using Surgiflo Hemostatic Matrix: A Novel Adjunct for Post-TAVR Access-Site Management. J Invasive Cardiol 2017 Aug;29(8):277-279
Date
08/02/2017Pubmed ID
28756421Scopus ID
2-s2.0-85026524758 (requires institutional sign-in at Scopus site)Abstract
Several options are available to address hemostasis at the end of a cardiac catheterization or percutaneous transfemoral transcatheter aortic valve replacement (TAVR) when conventional options are ineffective. To date, there have been few studies exploring the use of a topical thrombin preparation, as one of its main contraindications is that it cannot be used intravascularly due to risk of embolization. The following case shows safe utilization of Surgiflo hemostatic gel matrix under fluoroscopic guidance against an inflated balloon in order to achieve closure of a fistulous tract from a femoral artery access site during percutaneous TAVR.
Author List
Gajo E, Iftikhar O, Pearson PJ, Feldman T, Guerrero M, Levisay J, Salinger MHAuthor
Paul Joseph Pearson MD, PhD Chief, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAortic Valve Stenosis
Catheterization, Peripheral
Computed Tomography Angiography
Cutaneous Fistula
Femoral Artery
Hemostasis, Surgical
Hemostatics
Humans
Male
Postoperative Hemorrhage
Transcatheter Aortic Valve Replacement
Treatment Outcome
Ultrasonography, Doppler
Vascular Fistula
